Oral magnesium administration prevents thermal hyperalgesia induced by diabetes in rats

Hasanein, Parisa; Parviz, Mohsen; Keshavarz, Mansoor; Javanmardi, Kazem; Mansoori, Marzieh; Soltani, Nepton

doi:10.1016/j.diabres.2005.12.004

Cited by 27 publications

(25 citation statements)

References 41 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Diabetic rats are reported to have decreased TFLs (Courteix et al, 1993;Lee & McCarty, 1992); however, the thermal nociceptive threshold is not altered up to 8 weeks after STZ injection (Gupta et al, 2003;Malcangio & Tomlinson, 1998). Consistently, these data and our previous works (Hasanein & Soltani, 2009;Hasanein et al, 2006 have also shown lower thermal pain thresholds in STZ-induced diabetic animals. RA long term oral administration reversed thermal hyperalgesia in the diabetic treated rats although did not affect on thermal pain threshold of healthy animals.…”

Section: Discussionsupporting

confidence: 80%

“…It has been demonstrated that diabetic rats display hyperalgesic behavior in response to noxious stimuli that may model aspects of painful diabetic neuropathy (Freshwater et al, 2002). For this reason, STZ-diabetic rats have been increasingly used as a model of painful diabetic neuropathy to assess the efficacy of potential analgesic agents (Hasanein & Soltani, 2009;Hasanein et al, 2006.…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Effects of rosmarinic acid on an experimental model of painful diabetic neuropathy in rats

Hasanein¹,

Zaheri²

2014

Pharmaceutical Biology

Self Cite

View full text Add to dashboard Cite

Context: Diabetic neuropathic (DN) pain is one of the diabetes complications. Rosmarinic acid (RA), a natural phenol antioxidant, shows some biological activities, including anti-inflammatory, analgesic, and anti-diabetic effects. Objectives: We investigated the efficacy of RA administration (10 and 30 mg/kg) on streptozotocin (STZ)-induced neuropathy in rats. Material and methods: The animals received saline or RA (10 and 30 mg/kg, p.o.; once daily) for 8 weeks. DN was evaluated by the tail flick (TF) method, formalin test, and tactile allodynia. At the end, all rats were weighed and underwent plasma glucose measurement. Results: There was an increase in licking time during both formalin test phases in diabetic animals (138.5 ± 10.7 and 448.7 ± 2.6 s) that was decreased by RA10 mg/kg (103.5 ± 7.5 and 284.4 ± 19 s) and RA 30 mg/kg (81.8 ± 11 and 192.7 ± 14 s). RA 30 mg/kg caused anti-nociception during the early phase in treated controls (52.1 ± 6 s) than untreated controls (99.4 ± 5.9 s). The TF latency in diabetics (2.9 ± 0.1 s) was increased in RA10 and 30 mg/kg treated diabetics (5.3 ± 0.4 and 6 ± 0.86 s). The paw withdrawal threshold (PWT) of the diabetics (3.6 ± 0.7 g) was increased after RA 10 and 30 mg/kg (13.8 ± 0.3 and 14 ± 0.4 g) treatment. RA did not induce a significant change in body weight and plasma glucose of rats. Conclusion: RA showed efficacy in amelioration of some aspects of DN. Therefore, RA makes a good candidate for DN treatment in clinical studies.

show abstract

Section: Discussionsupporting

confidence: 80%

Section: Discussionmentioning

confidence: 99%

Effects of rosmarinic acid on an experimental model of painful diabetic neuropathy in rats

Hasanein¹,

Zaheri²

2014

Pharmaceutical Biology

Self Cite

View full text Add to dashboard Cite

show abstract

“…In agreement with our study, the findings of a recent report showed a significant reduction in plasma magnesium levels in diabetic animals. However, this condition was restored by 8-week oral magnesium administration, correcting the thermal pain threshold and plasma glucose level [24].…”

Section: Discussionmentioning

confidence: 99%

“…Neuropathic pain is a chronic pain manifested by a change in pain nociception, accelerated feeling of pain in response to painful stimuli (hyperalgesia), and abnormal painful sensitivity to those stimuli that were not painful earlier (allodynia) [23]. In an acute thermal test for pain processing, which involved measurement of pain threshold through tail flick latency, it was shown that oral magnesium administration prevents thermal hyperalgesia induced by diabetes in rats [24]. In agreement with our study, the findings of a recent report showed a significant reduction in plasma magnesium levels in diabetic animals.…”

Section: Discussionmentioning

confidence: 99%

Effect of Magnesium Administration on Passive Avoidance Memory and Formalin-Induced Nociception in Diabetic Rats

Sarreshtehdar¹,

Gheibi²,

Ziaee³

et al. 2013

Trop. J. Pharm Res

View full text Add to dashboard Cite

“…Magnesium deficiency induces sensitization of nociceptive pathways which involves NMDA receptors. Oral administration of magnesium can restore thermal hyperalgesia and magnesium deficiency in diabetic rats (Hasanein et al 2006).…”

Section: Discussionmentioning

confidence: 99%

Additive and antagonistic antinociceptive interactions between magnesium sulfate and ketamine in the rat formalin test

Vujović¹,

Vučković²,

Vasović³

et al. 2017

Acta Neurobiologiae Experimentalis

View full text Add to dashboard Cite

Because ketamine and magnesium block NMDA receptor activation by distinct mechanisms of action, we hypothesized that in a model of inflammatory pain in rats the combination of ketamine and magnesium might be more effective than ketamine alone.Antinociceptive activity was assessed by the formalin test in male Wistar rats (200-250 g). Animals were injected with 100 μL of 2.5% formalin to the plantar surface of the right hind paw. Data were recorded as the total time spent in pain-related behavior after the injection of formalin or vehicle (0.9% NaCl).Ketamine and magnesium sulfate given separately reduced nocifensive behavior in the second phase of the formalin test in rats.When ketamine was applied after magnesium sulfate, the log dose-response curves for the effects of ketamine and the magnesium sulfate-ketamine combination revealed antagonistic interaction, and about 1.6 (CL 1.2-2.4) fold increment in ketamine dosage. A low dose of magnesium sulfate (5 mg/kg, subcutaneously) administered after ketamine increased the antinociceptive effect of ketamine by a factor of only 1.2 (CL 0.95-1.38), indicating an additive interaction. There was a 1.8-fold reduction in dosage of ketamine when ketamine was administered before rather than after the magnesium sulfate.The present study revealed that both ketamine and magnesium reduced pain-related behavior in the second phase of the formalin test in rats. Ketamine, when administered before or after the magnesium, provided additive or antagonistic antinociceptive interactions, respectively. Whether there will be an additive or antagonistic antinociceptive interaction between ketamine and magnesium depends on the order of drug administration.

show abstract

Oral magnesium administration prevents thermal hyperalgesia induced by diabetes in rats

Cited by 27 publications

References 41 publications

Effects of rosmarinic acid on an experimental model of painful diabetic neuropathy in rats

Effects of rosmarinic acid on an experimental model of painful diabetic neuropathy in rats

Effect of Magnesium Administration on Passive Avoidance Memory and Formalin-Induced Nociception in Diabetic Rats

Additive and antagonistic antinociceptive interactions between magnesium sulfate and ketamine in the rat formalin test

Contact Info

Product

Resources

About